OBJECTIVE: To estimate the prevalence, incidence, and clearance of abnormal vaginal cytology and vaginal intraepithelial neoplasia (VAIN) in human immunodeficiency virus (HIV)-seropositive women. METHODS: Pap tests were done semiannually for 335 HIV-seropositive and 75 HIV-seronegative women with prior hysterectomy in the prospective Women's Interagency HIV Study cohort. End points included abnormal Pap test results after hysterectomy and VAIN regardless of hysterectomy. RESULTS: Over a median of 5.6 years of follow-up, vaginal Pap test results were abnormal at 1,076 (29%; 95% confidence interval [CI] 25-33%) of 3,700 visits among HIV-seropositive compared with 31 (4%; 95% CI 2-8%) of 763 visits among HIV-seronegative women (P<.001). Abnormal Pap test results included 641 atypical squamous cells of undetermined significance, 425 low-grade squamous intraepithelial lesions, and 10 high-grade squamous intraepithelial lesions in HIV-seropositive women and 28 atypical squamous cells of undetermined significance and three low-grade squamous intraepithelial lesions in HIV-seronegative women. The incidence of abnormal Pap test results after hysterectomy was 14 per 100 person-years among HIV-seropositive and two per 100 person-years among HIV-seronegative women (P<.001) and remained stable across time. The 5-year clearance rate of abnormal Pap test results was 34 per 100 person-years for HIV-seropositive and 116 per 100 person-years for HIV-seronegative women (P<.001). In multivariate regression models, women with lower CD4 counts were more likely to have and less likely to clear abnormal cytology when it occurred. The incidence of VAIN 2 or worse was 0.2 and 0.01 per 100 person-years for HIV-seropositive and HIV-seronegative women (P=.001). Two HIV-seropositive women developed stage II cancers with remission after radiotherapy. CONCLUSION: Vaginal Pap test results are often abnormal in HIV-seropositive women. Although more common than in HIV-seronegative women, VAIN 2 or worse and especially vaginal cancers are infrequent.
OBJECTIVE: To estimate the prevalence, incidence, and clearance of abnormal vaginal cytology and vaginal intraepithelial neoplasia (VAIN) in human immunodeficiency virus (HIV)-seropositive women. METHODS:Pap tests were done semiannually for 335 HIV-seropositive and 75 HIV-seronegative women with prior hysterectomy in the prospective Women's Interagency HIV Study cohort. End points included abnormal Pap test results after hysterectomy and VAIN regardless of hysterectomy. RESULTS: Over a median of 5.6 years of follow-up, vaginal Pap test results were abnormal at 1,076 (29%; 95% confidence interval [CI] 25-33%) of 3,700 visits among HIV-seropositive compared with 31 (4%; 95% CI 2-8%) of 763 visits among HIV-seronegative women (P<.001). Abnormal Pap test results included 641 atypical squamous cells of undetermined significance, 425 low-grade squamous intraepithelial lesions, and 10 high-grade squamous intraepithelial lesions in HIV-seropositivewomen and 28 atypical squamous cells of undetermined significance and three low-grade squamous intraepithelial lesions in HIV-seronegative women. The incidence of abnormal Pap test results after hysterectomy was 14 per 100 person-years among HIV-seropositive and two per 100 person-years among HIV-seronegative women (P<.001) and remained stable across time. The 5-year clearance rate of abnormal Pap test results was 34 per 100 person-years for HIV-seropositive and 116 per 100 person-years for HIV-seronegative women (P<.001). In multivariate regression models, women with lower CD4 counts were more likely to have and less likely to clear abnormal cytology when it occurred. The incidence of VAIN 2 or worse was 0.2 and 0.01 per 100 person-years for HIV-seropositive and HIV-seronegative women (P=.001). Two HIV-seropositivewomen developed stage II cancers with remission after radiotherapy. CONCLUSION: Vaginal Pap test results are often abnormal in HIV-seropositivewomen. Although more common than in HIV-seronegative women, VAIN 2 or worse and especially vaginal cancers are infrequent.
Authors: J M Palefsky; H Minkoff; L A Kalish; A Levine; H S Sacks; P Garcia; M Young; S Melnick; P Miotti; R Burk Journal: J Natl Cancer Inst Date: 1999-02-03 Impact factor: 13.506
Authors: Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young Journal: Clin Diagn Lab Immunol Date: 2005-09
Authors: L Stewart Massad; Charlesnika Evans; Kathleen Weber; Helen E Cejtin; Elizabeth T Golub; Kathy DiGilio; Amy Alpern; D Heather Watts Journal: J Acquir Immune Defic Syndr Date: 2007-04-15 Impact factor: 3.731
Authors: Xiaonan Xue; Stephen J Gange; Ye Zhong; Robert D Burk; Howard Minkoff; L Stewart Massad; D Heather Watts; Mark H Kuniholm; Kathryn Anastos; Alexandra M Levine; Melissa Fazzari; Gypsyamber D'Souza; Michael Plankey; Joel M Palefsky; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-01 Impact factor: 4.254
Authors: Gypsyamber D'Souza; Robert D Burk; Ye Zhong; Howard Minkoff; L Stewart Massad; Xiaonan Xue; D Heather Watts; Kathryn Anastos; Joel M Palefsky; Alexandra M Levine; Christine Colie; Philip E Castle; Howard D Strickler Journal: Int J Cancer Date: 2012-01-03 Impact factor: 7.396
Authors: Ralph P Insinga; Kai-Li Liaw; Lisa G Johnson; Margaret M Madeleine Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-07 Impact factor: 4.254
Authors: L Stewart Massad; Eric C Seaberg; Rodney L Wright; Teresa Darragh; Yi-Chun Lee; Christine Colie; Robert Burk; Howard D Strickler; D Heather Watts Journal: Obstet Gynecol Date: 2008-06 Impact factor: 7.661
Authors: L Stewart Massad; Xianhong Xie; Howard L Minkoff; Katherine G Michel; Gypsyamber D'Souza; Chia-Ching Wang; Deborah Konkle-Parker; Igho Ofotokun; Margaret A Fischl; Lisa Rahangdale; Howard D Strickler Journal: Am J Obstet Gynecol Date: 2021-05-03 Impact factor: 10.693
Authors: Lunthita M Duthely; Jose A Carugno; Cayla Y Suthumphong; Erica B Feldman; JoNell E Potter Journal: Interdiscip Perspect Infect Dis Date: 2019-01-01